Clinical Trials Logo

Clinical Trial Summary

Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite.

Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01570504
Study type Interventional
Source Centro per le Malattie Tropicali
Contact
Status Completed
Phase Phase 3
Start date March 2013
Completion date June 8, 2018

See also
  Status Clinical Trial Phase
Completed NCT04999774 - Evaluation of Strongyloidiasis in Ecuador: a fieLd Laboratory Accuracy Study
Recruiting NCT05868005 - Delivering a Multi-disease Screening Tool to Migrant Populations N/A
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Terminated NCT03605758 - Treatment of Strongyloides Infection Phase 3
Recruiting NCT06373835 - Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis Phase 2
Completed NCT02105714 - Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders N/A
Not yet recruiting NCT04709848 - Strongyloides Stercoralis in Bone Marrow Transplant Recipients in the UK
Completed NCT00207753 - Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections N/A
Completed NCT00001245 - Study of Patients With Strongyloides Stercoralis Infection N/A